Source link : https://www.newshealth.biz/health-news/apoa1-trial-misses-endpoint-but-hdl-hypothesis-still-alive/
A human apolipoprotein A1 (ApoA1) product, which is the key constituent of high-density lipoprotein (HDL) cholesterol and removes excess lipid from atherosclerotic plaques, did not bring about a significant reduction in the primary endpoint of cardiovascular death, myocardial infarction (MI), or stroke in patients with MI and additional risk factors, in the AEGIS-II trial. But […]
Author : News Health
Publish date : 2024-04-06 20:41:57
Copyright for syndicated content belongs to the linked Source.
Categories